Betaseron
information and resources from the National Cancer Institute
NCI Thesaurus | Betaseron
(Other name for: recombinant interferon beta)NCI Thesaurus | Betaseron
(Other name for: recombinant interferon beta)
|
|
|
|
news articles
Tysabri poised for return to market 01 Apr 2006
Pharmaceutical Business Review Schering AG's Betaferon/Betaseron (interferon beta- 1b), Teva Neuroscience's Copaxone (glatiramer acetate), Serono SA's Novantrone (mitoxantrone hydrochloride ...
Prescription headaches Mar 31, 2006
Fort Wayne Journal Gazette, Now, due to the prescription Medicare Part D drug plan and rules surrounding it, she fears she might have to discontinue the drug – Betaseron – again. ...
Merck Withdraws After Bayer Tops Bid for Schering Mar 24, 2006
New York Times, It will also get its hands on the multiple sclerosis treatment Betaseron, which Schering expects will reach 1 billion euros ($1.2 billion) in annual sales. ...
Bayer on the verge of Schering buyout Mar 26, 2006
Irish Examiner, It will also get its hands on multiple sclerosis treatment Betaseron, which Schering expects will reach €1 billion in annual sales. ...
Bayer as white knight edges out Merck in bid for Schering Mar 25, 2006
ABCmoney.co.uk, The acquisition will bring to its fold Schering's top-selling oral birth control drug Yasmin and multiple sclerosis drug Betaseron. ...
Bayer Bids 16.3 Bln Euros for Schering, Topping Merck, WSJ Says Mar 23, 2006
Bloomberg ...drugs. Schering is the world's largest birth-control pill maker, and also sells the Betaseron multiple sclerosis treatment. Oliver ...
Bayer Offers to Buy for Schering for EU16.3 Bln, Topping Merck Mar 23, 2006
Bloomberg ...to 84.97 euros after newspapers reported a Bayer bid is likely, is the world's largest birth-control pill maker and also sells the Betaseron multiple sclerosis ...
Local man receives first Avastin treatment Mar 17, 2006
StarPhoenix, Rak looks for inspiration to the fight that occurred around the multiple sclerosis drug Betaseron in 1998 before the government decided ultimately to cover its ...
A Pick-Me-Up for German Pharma Mar 24, 2006
BusinessWeek Schering brings Yasmin, the world's top-selling contraceptive, and Betaseron, a treatment for multiple sclerosis, which is expected to pull in $1 billion in ...
Bayer set to seal £11bn Schering takeover after Merck pulls out Mar 24, 2006
Independent, Bayer will also get its hands on Schering's multiple sclerosis treatment Betaseron, which is expected to reach €1bn in annual sales. ...
Avaricious In Germany Mar 24, 2006
Forbes ...under the name of Berlex Laboratories in the US, is a big player in birth-control pills, has blockbuster in the multiple sclerosis treatment Betaseron, and is ...
Schering defeat seen forcing German Merck to act Mar 27, 2006
Reuters ...declined to comment when asked if it could look at Serono, whose most important drug is Rebif, a multiple sclerosis treatment that rivals Schering's Betaseron. ...
Drug coverage inconsistent Mar 14, 2006
StarPhoenix, ...to drug coverage. Back in 1998, the province went through a similar debate on a multiple sclerosis drug called Betaseron. In that ...
Wonder drugs don’t exist for MS; stick with proven options Mar 26, 2006
Fort Wayne Journal Gazette, Interferon beta-1b (Betaseron), interferon beta-1a (Avonex, Rebif), glatiramer (Copaxone), and mitoxantrone (Novantrone) are only partially effective in the ...
Bayer Makes Move To Buy Schering AG Mar 25, 2006
Medical News Today (press release), The products in this area include Schering's top-selling Betaseron® for the treatment of multiple sclerosis and Leukine®, used to boost a patient's immune ...
Bayer bids for Schering to renew drug unit Mar 24, 2006
Shanghai Daily, Schering, whose fourth-quarter earnings rose 18 percent, gets 16 percent of sales from the Betaseron multiple sclerosis treatment. ...
Schering to buy or lease all Chiron assets used to produce ... Feb 27, 2006
Forbes ...under their joint collaboration agreement to purchase or lease all assets used by Chiron in the manufacture for Schering of MS drug Betaseron interferon beta ...
Schering Shares Rise on Report of Possible Bayer Bid (Update2) Mar 23, 2006
Bloomberg Schering is the world's largest maker of birth-control pills, and gets about 16 percent of sales from the multiple sclerosis treatment Betaseron. ...
Bayer in €16.3bn agreed bid for Schering Mar 23, 2006
MSNBC It derives around 16 per cent of its sales from Betaseron, a multiple sclerosis treatment and also makes substances introduced into the body to make organs ...
Bayer Plans to Cut 6,000 Jobs After Schering Purchase (Update2) Mar 24, 2006
Bloomberg Schering, whose fourth-quarter profit rose 18 percent, gets 16 percent of sales from the Betaseron multiple sclerosis treatment. ...
Schering shares surge as Bayer rides to rescue Mar 24, 2006
ABC News Bayer access to Schering's contraceptive Yasmin, the world's top-selling oral birth-control drug, and multiple sclerosis treatment Betaseron, which Schering ...
Tysabri delayed as rivals gird Mar 22, 2006
Boston Globe, Teva's Copaxone achieved sales of nearly $1.2 billion, and Schering AG's Betaseron reached sales of nearly $1.1 billion last year. ...
Schering Hires Morgan Stanley, Dresdner for Defense (Update1) Mar 15, 2006
Bloomberg ...the dividend Feb. 20, and he's planning to buy all rights to the multiple sclerosis drug Betaseron from Chiron Corp. He may use ...
Schering Accepts Bayer's EUR 16.3 Bln Cash Takeover Offer, To Form ... Mar 23, 2006
Trading Markets, The products in this area include Schering's top-selling Betaseron for the treatment of multiple sclerosis and Leukine, used to boost a patient's immune system ...
Pfizer CEO Earned Nearly $16 MLN in 2005 and Chiron Confirms ... Feb 27, 2006
Financial News USA (press release), ...under its collaboration agreement with Chiron to purchase or lease all assets used by Chiron in the manufacture for Schering of BETASERON® interferon beta-1b ...
Bayer rides forth as Schering's white knight Mar 24, 2006
Pharma Times (subscription), ...brings a market-leading hormonal therapies business, including the blockbuster Yasmin oral contraceptive franchise, cancer drugs and Betaseron (interferon beta ...
Address by Werner Wenning Mar 24, 2006
PharmaLive.com (press release), These include the top-selling Schering drug Betaseron ® and two other growth drivers: Schering's Leukine ® and Bayer's Kogenate ® , which also has ...
German Merck won't top Bayer's Schering bid Mar 24, 2006
Investor's Business Daily (subscription) In addition to being a leading manufacturer of contraceptives, Schering markets the multiple-sclerosis drug Betaseron and has been engaged in gene-therapy ...
FDA asks panel to weigh benefits, risks of Tysabri Mar 6, 2006
MarketWatch ...rate "appears to be twice the benefit of currently available first-line treatments for MS," which also include Serono SA's (SRA) Rebif, Betaseron, by Berlex Inc ...
Merck KGaA Makes EU14.9 Billion Offer for Schering AG (Update3) Mar 12, 2006
Bloomberg ...last week even as the company cut its forecast for a new menopause drug and the threat of more competition for multiple sclerosis drug Betaseron loomed with ...
FDA panel to weigh benefits, risks of Tysabri Mar 6, 2006
MarketWatch ...twice the benefit of currently available first-line treatments for MS." Other first-line treatments include Serono SA's (SRA) Rebif, Betaseron, by Berlex Inc ...
Schering says German rival Merck plans bid Mar 12, 2006
Scotsman, Schering's pharmaceuticals unit, on the other hand, depends on two key growth drivers -- its top drug, multiple sclerosis treatment Betaseron, and birth ...
Biogen, Elan Shares Jump After Getting US Support on Tysabri Mar 9, 2006
Bloomberg Tysabri may have sales of more than $1 billion a year, stealing revenue from rival products such as Serono SA's Rebif and Schering AG's Betaseron, analysts said ...
MS Guessing Game Heats Up Mar 9, 2006
TheStreet.com Cramer's Take), the maker of Copaxone, and Germany's Schering AG (SHR:NYSE - commentary - research - Cramer's Take), the seller of a drug called Betaseron. ...
Schering Cuts Angeliq Sales Forecast; Shares Fall (Update2) Mar 10, 2006
Bloomberg Chief Executive Officer Hubertus Erlen is relying on the 17-year-old Betaseron multiple sclerosis treatment, which garnered more than $1 billion in revenue ...
German Stocks Rise, Paced by Schering; Siemens Gains on Order Mar 9, 2006
Bloomberg A potential reintroduction of the Tysabri multiple-sclerosis drug won't be ``a major threat'' to Schering's Betaseron, said Isabella Zinck, an analyst at HVB ...
Schering Hires Morgan Stanley, Dresdner to Prepare Defense Mar 15, 2006
Bloomberg Erlen said in February that he plans to take full control of the rights to multiple sclerosis drug Betaseron by buying out a manufacturing agreement with ...
Ratiopharm: competes with Stada, Sandoz on biogeneric drugs Mar 8, 2006
MarketWatch German drug maker Schering sells Interferon beta under the name Betaseron and saw 2005 sales of EUR867 million, up 10% on the year. ...
Tysabri Return To Market: First-Line Use In Relapsed Multiple ... Mar 8, 2006
FDA Advisory Committee ...any of the other available first-line therapies (beta interferon (Biogen Idec’s Avonex, Serono/Pfizer’s Rebif, Berlex/Chiron’s Betaseron) or glatiramer ...
Chiron Recalls Its Morupar Vaccine; Revises Q4, FY05 Results ... Mar 16, 2006
Trading Markets, Chiron said, last month, that Schering AG agreed to purchase its assets used to manufacture Betaseron interferon beta-1b products to treat multiple sclerosis. ...
Schering Not Seen Hit By Return Of Tysabri Mar 9, 2006
newratings.com ...fatal brain infection. HVB says if Tysabri receives FDA approval it shouldn't be a major threat to Schering's betaseron. Says given ...
Tysabri should return to market, says FDA panel Mar 9, 2006
Pharma Times (subscription), ...with other MS drugs, such as Biogen Idec's own Avonex (interferon beta-1a), Serono's Rebif (interferon beta-1a), Berlex/Chiron's Betaseron interferon beta-1b ...
Biogen foresees Tysabri re-launch by June Mar 9, 2006
Investor's Business Daily (subscription) Most of the current leading therapies -- Serono's Rebif, Biogen's Avonex, and Schering AG's Betaseron -- must be administered by needle more frequently than ...
ValueAct Capital Refuses to Meet with Chiron Directors Except to ... Mar 15, 2006
Business Wire (press release), February 21, 2006 - Schering AG announces it will exercise its option to buy Chiron's marketing rights to Betaseron, a product contributing roughly one ...
Manhattan Research Reveals Top Ten Consumer-Ranked Pharmaceutical ... Mar 7, 2006
PR Newswire (press release), Abilify, Accupril, Actonel, Actos, Adderall, Advair, Allegra, Amaryl, Ambien, Androgel, Aricept, Arimidex, Avandia, Avastin, Avelox, Betaseron, Bextra, Biaxin ...
Drug stocks decline, Vertex falls on drug data Mar 9, 2006
Investor's Business Daily (subscription) ...sells Copaxone, fell 1% to $40.68. Schering AG (SHR), which produces Betaseron, was the biggest gainer, closing up 6% at $78.30.
Two-Day Tysabri Hearing Drawing Intense Attention Mar 3, 2006
BioWorld Online (subscription), ...in the multi-billion-dollar MS market include four disease-modifying therapies: Avonex (beta interferon 1a, also from Biogen Idec), Betaseron (beta interferon ...
Schering- has purchase option on Betaseron rights Dec 9, 2005
Reuters Schering (SCHG.DE: Quote, Profile, Research) said on Friday it has a purchase option for rights to market multiple sclerosis drug Betaseron, but declined to ...
Schering must decide soon on Betaseron move -paper Dec 8, 2005
Reuters ...must decide soon on whether to pay up to 1 billion euros ($1.18 billion) to maintain exclusive marketing rights for multiple sclerosis drug Betaseron, a German ...
Schering May Have to Pay to Protect Betaseron (Update1) Dec 9, 2005
Bloomberg Dec. 9 (Bloomberg) -- Schering AG, Germany's third- largest drugmaker, may have to buy rights to its Betaseron medicine to protect its single biggest source of ...
Schering May Buy Full Rights to Betaseron Drug From Chiron Dec 9, 2005
Bloomberg Dec. 9 (Bloomberg) -- Schering AG, Germany's third-largest drugmaker, may buy the full rights to the multiple sclerosis therapy Betaseron drug from Chiron Corp ...
Schering must decide soon on Betaseron -paper Dec 9, 2005
Reuters ...decide soon on whether to pay up to 1 billion euros ($1.18 billion) to maintain exclusive marketing rights for multiple sclerosis drug Betaseron, the Financial ...
NEWS SNAP: Schering May Pay Out To Protect Its Key Drug Dec 9, 2005
Business Online, ...that analysts say could cost it $1 billion, but would give it the chance to fend off generic competition to its best-selling multiple sclerosis drug, Betaseron ...
European Indexes Down at Midday Dec 9, 2005
BusinessWeek In another development, Schering may have to pay €1 billion to keep the exclusive rights to market multiple sclerosis treatment Betaseron. ...
Schering can buy Betaferon rights but says reported 1 bln eur cost ... Dec 9, 2005
Forbes Schering acquired the right to market the Chiron-discovered multiple scleroris drug Betaferon -- named Betaseron in the US -- in 1993. ...
Yaz Delay Not Detrimental For Schering Dec 9, 2005
New Ratings ...the Chiron (CHIR) contract may create some overhang, but is just a "technicality." Further, doesn't expect overall fundamental economics of Betaseron drug to ...
MS is unpredictable disease Dec 8, 2005
Georgetown Record, ...never been more hopeful.As recently as 1993, there were no FDA approved drugs for the treatment of MS.Now, there are five (Avonex, Betaseron, Copaxone, Rebif ...
DaimlerChrysler, EADS, Roche, Schering: European Equity Preview Dec 8, 2005
Bloomberg ...third-largest drugmaker may have to pay 1 billion euros to keep the exclusive rights to market the multiple sclerosis treatment Betaseron, Financial Times ...
European Stocks Fall, Led by STMicroelectronics; BP Declines Dec 9, 2005
Bloomberg Financial Times Deutschland reported the company may have to pay 1 billion euros ($1.2 billion) to keep the exclusive rights to market Betaseron. ...
European Stocks May Fall, Led by STMicroelectronics, Infineon Dec 8, 2005
Bloomberg ...reported the company may have to pay 1 billion euros ($1.18 billion) to keep the exclusive rights to market the multiple sclerosis treatment Betaseron. ...
European stocks end touch off, pricier oil unnerves Dec 9, 2005
Reuters.uk, ...weighing on the German drugmaker was news that it was weighing an option to buy exclusive marketing rights to multiple sclerosis drug Betaseron developed by ...
AFX European Summary - Midday Dec 9, 2005
Forbes Schering acquired the right to market the Chiron-discovered multiple scleroris drug Betaferon -- named Betaseron in the US -- in 1993.
Euroshares lower midday on Wall St losses, VNU rises on takeover ... Dec 9, 2005
Forbes ...approval of its YAZ contraceptive and amid a report Schering may have to pay 1 bln eur to secure the exclusive rights to market MS drug Betaseron, dealers said ...
German shares lower midday on US losses; Schering dips on YAZ and ... Dec 9, 2005
Forbes ...of its YAZ contraceptive and amid a report Schering may have to pay 1 bln eur to secure the exclusive rights to market MS drug Betaferon (Betaseron in the US). ...
Germany's DAX Falls; Schering, Infineon, Lufthansa Shares Slide Dec 9, 2005
Bloomberg 9 (Bloomberg) -- German stocks slipped, led by Schering AG. The world's biggest maker of birth-control pills may buy full rights to Betaseron from Chiron Corp. ...
German Stocks Fall, Led by Schering, Infineon and Lufthansa Dec 9, 2005
Bloomberg The company may buy full rights to the multiple sclerosis treatment Betaseron from Chiron Corp., which produces the drug in the US. ...
Schering "buy" Dec 9, 2005
New Ratings The FDA has also asked Schering to invest €1 billion for the exclusive marketing rights of Betaseron, following patent expiry due in 2008 on account of the ...
Elan Tysabri Expected: May Still Boost Shrs Nov 18, 2005
New Ratings ...being re-approved) is slim." That said, expects Serono (SRA) and Schering (SCH.XE) to be weaker due to their exposure to MS via Rebif and Betaseron respectively ...
|
|
